Obexelimab (anti-CD19) is a humanized anti-CD19 antibody Fc-engineered for increased affinity to FcγRIIb. Obexelimab (anti-CD19) can be used in research of autoimmune. Purity≥95% (SDS-PAGE&SEC) Endotoxin Level < 0.01EU/μg
Product Properties
Isotype
Human IgG1
Light Chain Type
kappa
SDS-PAGE
26.5 kDa (Light Chain) & 50.4 kDa (Heavy Chain), under reducing conditions; 196.1 kDa, under non-reducing conditions.
Purification Method
Protein A purified
Form
Liquid
Concentration
Lot by Lot
Storage Temp
Store at -80°C,Avoid repeated freezing and thawing
Shipped In
Ice chest + Ice pads
Stability And Storage
Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS
1690307-05-1
Images
Obexelimab (anti-CD19) (Ab182851) - Flow Cytometry Flow Cytometry analysis of human peripheral blood lymphocytes labelling CD19 with Obexelimab (anti-CD19) (Ab182851) conjugated with biotin (right panel) compared with Human IgG (Biotin) (Ab180314) - Isotype Control (left panel) and detected with SA-PE (rp156150).
Obexelimab (anti-CD19) (Ab182851) - Flow Cytometry Flow Cytometry analysis of human peripheral blood lymphocytes labelling CD19 (red) with Obexelimab (anti-CD19) (Ab182851) conjugated with biotin and detected with SA-PE (rp156150). Blue - Isotype control, Human IgG (Biotin) (Ab180314). Black - Unlabelled control, cells without incubation with primary antibody.
Obexelimab (anti-CD19) (Ab182851) - SEC The purity of Obexelimab (anti-CD19) (Ab182851) is more than 95% verified by HPLC.